{"ticker": {"uuid": "604cccad-4f2b-4f19-abc6-f185aac76766", "symbol": "SRPT", "name": "SAREPTA THERAPEUTICS INC", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Sarepta Therapeutics Stock Short Interest Rises to 32.62%", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPU3pNcWJKQ3piVXczNkJiMjZ3LUNhVVlaUmVWTzg2ZFZhclR0OHhSNXlCdzdDbktjM3ppbjZ5N2xSVlVMTUdMNGduRkJ0czh4QXNoS2ZPTi12djZwSVNCeDFUT2QxRUVCUVZqY05WcU84N2U0U3NRd0NrQmxyM0dEbWllWmtRVkxNa0xDNU15amJZdWpPVTlB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T13:28:00+00:00", "published_display": "21 Jul 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T02:26:36+00:00", "published_display": "19 Jul 2026 02:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObk51bU1mR3FzU2NEWnN0YnJqQkloRVVSMDR5aHZoNlJ2UHVqNGlZdWdIQ2MxNUh0bGM5LVp5dTA3ajEzQ2ZpczFoWkE4YjM4dDhsTWVtUzk0a2xGYnZMSWh1STVDLTljQWg0Sm1mSDJoUkhvR1RCVzcxUUJKOWkwZHhfd3hVZHdhNWVMMGU5THE1TlRNeXZwVjhtRWg?oc=5", "source_name": "Market source", "published_at": "2026-07-14T00:22:00+00:00", "published_display": "14 Jul 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUG1ibFpjUk42WE1FblNsd2tPWS1qZUFFY1VhTGg3d1hGOGJfS0dVTDk1R1JkUlV3dk9QaTRmTkNDMmVpZXNhSnpSX1Q0TTNLYVgyNXd6T09kb3dfbnh2dnpORkVIdnhMNWx6NElvTTJXNFk4eFRNWGhiYlE5aXY5VzlhZU9yV3UxWFkxSzdSbmplVTRZWlJseU9jWU9uRDJva28tdzhZUzN5RDFtdG5qM2xyMXZjbmFsYXZtbW9OTUhKNkh4Z19ISFR1cXNmTFV2S0hGZHpIcmVmRUZROTNYWl9sYWxPX0J1Z0o2YWY2V0xCU2hYbFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:33+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQekUxZnVlZXpCSFcxOHpjU3dVTlBGOTFzakJnX1pVb3EzVDZlNm1TLW84aU1sTGpXZnNOTEVkVEFnVHlFem1ET0JsY0x1Uy15d25JV0dZLXNVQnZwaTVpeXVVTXgxU0YyQ3J1bHlyWGFhWGdhbmc2VmhwRTctanJ2WURjYVVZTFFLRmNadWJldDdsdHU2V1c0ZHlabTM0aGhkTDV3Z3hzQmhrS0VIZmxhVE5JSGlXYjhZajBpYWRuZEdnUHZwWGtCUmh2RVlUM3dRQS00?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics options trading jumps to 5,295 contracts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOXYtV0ZEV2J3WjRUUi13anhKNUVMOGZYY1czRkV3MWQ1TXNCUFdnX0lScmlSeVdhU1lVSlEzakViZDhvaEdicXBIMXkzbGcwMTI2Z2lJTi1LalhlOHc2eFN4eXZRTkdDbXhXRUZtQktOOFYwOTZHeUdrUFZ6VWNQVDVzZjk1ZHRENUZJNmZsQ0c4bVVQT0VlWUVZTmhjbk4zR0JnZzl3V3AySG9KQ0RjNmdxU204a1pucjlheXp2MA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPeGtMV3dsYmlHdnZYTnBPcUdBb0l0Q3hnZy1nNEl1UklOX3ZiMzcxd3NGOElOcF9ybEttYldnOHpCOW5qMExmc25XYkdhTU9UNlBNTExiMm5YdWJpS2o2cXpMSTNGcndtT1B3ekVwOVg4TmNtU0ViVFJHRXN1OWhVbENNZ0ZTcHJrTnFNOUdNTjlselA3Zld4TUhjQWIyUU1tYno4cFJOMFhhWWhBRS1MeGw3UDFHYV9Ea1JZZDZDcU1SYVctYlp1a3RZRVRJVVgzVWlISzNkT2hjU1duMERhU2xUREFCZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQWTEzWXI2NXhNMFlmREM0Yzl0elQ0WWtuTG1uV0ZWUnlaMG9Feno0OVg3cGV2WXZqZ0U1NVpFWTZobGdZU01GUF8tU01fZWVLUDFRSXlxV0oxamdIbEFIbTM1cDVxNjFKQkM1RmZjMWVlVW9ITFBVYmIyOENmMG5Xd0ZnYm1DZkMxcHN0c21BaDNLTUF2b0VDenEtU05oOHk4MmVQMTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQRmZDQzFrS0t1SGk1OGx0SF8xZVhzSEIyVEtyRklrYjdrWHpXbGYzalV4UFZZbzNnWmkyaEppWl9uRDJIcUFWLWRJWkJqQ2RkeUp3cWZUYkxoU2Y2MWVqVnplakpNdXhUNXhMQmgxeTV3bjY1N3d0cUhFbGVOcEl5RVZZMV96Q3B4VVVQUVFVbzEycWNFTUEzUHhORHlZM2NIZ2pfMU5weTdsRkZJMmFlTUVwb1pSUnEycnYxWlpjMF9Pb0VndDNQMGMtemEtUjdxNzIxa1lvdi04MUVNOTlhaWdR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTh2S3pWR3ZmN3YyN0twbGhqb2tROXV6REtUN21xODh4MWhNR0pEb3VKb1N6VE9UUkprN3lQb052OGl2ZE5FdUdsMEtlWkIyRE1wTm1OR1RabkZYQm10TExvTFcxMk5iaUU2WlhkaFIyekdna2pRRGpGejBHZjA2MkV3Zkc3bXpFbHR4MFpSem5tZ0dvc0liSVZ6Y2xxMU9HREtwU2Y3N0pwSTQyWFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZVBVbDFVMnJpUlo4NVN3SDVmQ01pMEE2NktHbVdhS0dUenotaUptTnJnOWF2dXhuUm5hdHozbHFCM1AwWG84LVA3OElZLW1SVC1JWWpMT2I3WGtESmN2WlZncUY4TlhPR1U2eDNFa1dURlVVWlBRUHVWNHl0ZzJHdDNmY2VFTU9OX2s2aFFEa1NIZDg1TFVDQ1pRQjFESWlXVnJWbGJsUjRLckRiV1Zr?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOR3hMTUpuOVg4X3dmZ056QmVEdko1SkUxbGJIcE00ZHBBNUpjN2JYSGxIOV9HT3lfLWotckZLRTVYUEdaT29fMFRZU3BtbjF3ZFY3bWY0emJYSkJHLUh6STZzV0VXSXBfMTJoSDJuVTIyMlJDdEZpQmZmdGdfUXlqM1NyWlhuMFY5Xzk5YUR6eXFzRF9KU0ZoeWNMMjRQZmR5NFhpZTNtMTVma21WbWpF?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics shares drop 10% on lower Elevidys revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcmZlM2VlUi1oOHU0MTNXdmhLREVqUmZ3d3dPV05BelIzMFVnbHExWEVLUFhad2pEUUtDbHlPamNMTGprSTItbk12UzN5QjZUbUM2VjVqWjM0TU9RVUhVZGN5ZS1DcHIzQV84dFBmdTNUVzRSQVZDWEhkS3ZZd1N5TDY1b3ZtbDkyaXpndUtvUDBPb0V1TmIxNjdlU2xCVHdHdG80VzFiSm5FMUJZdnpRM2VyaXFpUkZWaUZLTkhwSjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Stock Falls as Investors Eye RNA Drugs, Despite Elevidys Gene Therapy Sales Outperforming Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxORFJfMXlKbjBCX2Y3MkxmajlwbzUtdGoxb29sdlJOWC1ZY3pBYnZXRzJwcmJSM29DUXVuVVBUaC1RLWFpczc5dDlTZ2JIa2dkX1lOcW82UnFjZF9ndkRRdmFPVkJpaTNoVXBmVjNOQ3M3Um95S2Q0R2NxRlNZWkh2X2Uzc1lyd0xpZjhFUjBKbDE0dzlpNzg4TGVCS0VmaEZmZVBRZVd1SnNQVXdjSm4wTmZkbVNiUVpiTkd4aWxNb2hfN3dmLVpqeE1tSXdOUWM?oc=5", "source_name": "geneonline.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNaS1Rb0lPUi1jNlpkSGpWd1g1V3FYN05mclpZamY3RDFNTGxKZG5wTVdQdl9TaGI0aXBQVVEzY05MLVRYSmk0ZDAwaGx5YmpaMmNPY0xQNHBoSTNzdjJwTXRxeXZEMkp6MHhvLTFyS3pvWDdFRHIzWmRnME9UX3hGLXBSUC1QaEpvUFRmNXhxY01IeEE3Wm1GZ1NKekw2STVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOamcwUjJmNDlTSWhXb2wyeEpGNmlEWWI3Z3RLSGpYdU5ROXBHTlJ1LUp1aU45d3JYUmt5ZnVjQnhqSnV1a0hQSWtPLUFyaTZTa1UxTG1GUmZlRXBaSXUxdUM5ZUlfWExES1ljUktSY3ZlbVhjZmRKcU9OOG9UcXRuVnpRdkgwUndPeV9zN1FpdTdHdzN5S3JVMkFKNEduazZNR19jOXROckFBaXAtNlVF?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta stock surges 14% on early siRNA trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPUzVGZk9jOFNrME80WjlLMDlOMmhDeU9nNlp1ZllBMklSWHlVekNDYUlDY2pBVmxfVnhPcV9pdEE2XzhBSE5Wa2NXYkxxaGFGT0VqTkhpLTJ0Zm9iNXk5QTFhYUJCOGp4STdGRnA0aVFaVXZtZS0tUGMyblc1dERpLUkxM095SkpESlE5TzZNUnJXeTExU0lvOWxmUXNCVWFhR2lDR1VTUWpuTkFJcFNDRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates Sarepta stock rating on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZHNiNkJBblc1cV9CWmdFSVRBTmhDeHV4cHhQMl9UTFpoUzQxVGVQbksxVnkwem1xZDREYko0MlhrMWVWMTlMc2FSVkpXWGNTUGJDNWY1bE5WM1B1aldsOURkRnc0WC1hdlFpaXFicnVsak1CdWVwWXptZklKLU96LUFnTDVQSWZXYnVudXJvX3lSR1pYM3dSRmVKN1NCWW42VjVvQlN4MHF2U01CUmlsQVNvcFp0a3ppNE83S3V3?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink reiterates Market Perform on Sarepta stock after siRNA data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcHFkUFFiNnVXQzFKaWx4c1FwVWtfN2hNZ2F0andXM1hsMzB2S0VBanUta3dYcnNMS1l3X3pEdWd0SlFBd2tOdE8yVkhLazFlejFIbnF6SmR4SE1mSFMyWkl5eHhPV0RObDlXSWNfZlZCMUtwX3htUUdTaG5sbXdwd2JwVzBFaTNTcFY1UXhBUFZYMzJablJUeGRyd0Y5MFo1UHZoQVhiTUI4djBEZHAxeTU3dUE0WXRySFZxOVVjS3RjTk1la2c?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOZDVxTV9xbXFhLVk3emNJVklnQ0NGT1pKUzFPQU0xVEdjblRhbGtTTDBVQlhnczV6MjlMMHl5blhqaHZnZUNjZHE5MjdES3g5TE1fQllhSWtXVU03ejlDX1RhWFRGYXlXTDVwY0dINUZ0T1lURVZscm01VVE0b1MyUTc3YWR2QkxtNlk0RXFtalpqcms2WDN2TDBOZHJ4djg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan maintains Neutral rating on Sarepta stock after positive 3-year data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQjVvS1dRcXZpU1hTVWhGT0o4djBfUG1UczZKam5uUmVVNmIyVU9WbEdsQlBJVXFBZjdFTWxDcjZtZWx1aTdBWUUwd2tvOWN5NGp3VVVuWVVSdDlUYllJRlJta3FyR254bUtfRDFuczJCRlA5UEFZcHJCVnZoTGo0QjJjamc4MEhDYnVJOExqYm5vaXFrZU1Wc2RPTk5lM2N3TjQ0YldaMDRCRERtRU5yekZPYllpWjV5M2stdTFnMXVLZXFSc1hyUDBpWUIzUDRrM2c?oc=5", "source_name": "Investing.com", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQZVFia2lQSldTSVNtT1JvNEd1aU5PYnF3dTR6QmRsUjZvaFhJV2hjSUpwSEdJYi1YYm00RHM4ZDdyamQ0ZDJmTFEyV0dIaFJqSTQtUmZoUldPN3JIQXk1YzkzM1lNa0w3OTVWNVZrSTdPNVNnMllFLUtSa1pfQXhiTnZUTVotYUhNMTYtQ1ZWNW5HdkJGZ1JaWV9TV2Iwa1V5bnF4LVRUYk5ELWR5eWxNbHgwaXBmaVhjQnpTNzJUX0RuR1VY?oc=5", "source_name": "Investing.com", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Falls After Gene Therapy Elevidys Misses Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNUlFEQ3IxaUFwT2pzaDUxVzQ4ZWR1c0N1Ykh1SThzODhYbVJxeUtXOEZMSnNlOWdOcC1TanlKTGo4bGlORG9PeWpCN2FWd2M4LVVpUW43S090YUhCeE9meTVZSXBGa2RuTU5WU1FIMVRXVXJCYlI4Rlp2ajU4ekNad1hSbnBDU3JXdEdUQlZxWU1leHhWN25VNklQU09GcVdnZGQzRmZmTFMzVmsyWnc?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares tumble on trial failure, weak Elevidys outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNNUM0N2d4V0VQU3BreE5TVmdBTWtsWkVhSEFqZ3FiY0RGNnd5Z2VwLUdlRjd2aHo0Q1FybnBuU3RmNlF3RW5VUmNzNE1BamhZRWY3aGtjaTQwSlZNcTB1NWF5QnVLQ2VsTm5fcDNqYUVWNkNuNUdtQVg1cm94Y0JZRl9DR3N2WDU4QVJFMG80YTczaXd2YmlPN3dsdzJ6OE1ERTRMczc2NlBWdXBsdExaLVB3OHRQTDA0eE1OdUl5dU1lQTYxU0pqQ3FXSQ?oc=5", "source_name": "Reuters", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Sarepta Stock Jump 20% On Tuesday? Here\u2019s What JPMorgan, Bernstein, Barclays Said About Elevidys", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOTmJLdXRqQ3JuejRqZTNobEs4MWtPN2lidlJZa3B1dUh0dzI2ZHJTY29nanBlbXdZeUtMZFp4aU4wV255ZnczQVltUEF5R1Z6Y2ZHckpqX1E2S2E1UGhxZ3I3Y05IaV9SWjBYWG9yWWF2M3NhQlA3S2JYcHM2Z3d0bVZ6amMzUDgzcXRFMHNnMHFwWU9QRk81WFF1ZDRNU05VUG9WUW01QzNQWHRKS1lqUzI5dk8?oc=5", "source_name": "Stocktwits", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares rebound after shipments of gene therapy Elevidys resume in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQT2ExUVAyeDBlSWc3cUUzS2tjVnZvVFFLY2g1ZU9iVk9kX3JpMjFDRnFHSHExUjNYVGlUWExzZnZhcndBYmVPN3hZZnVMb0ZZREdMSlFrRzdKRXVLb09scS1HcFBETTJDaDdoZ0tITDl6cF9CYTM4OTVFeldUeGMxMkdTSGtFX0U3bkFsMmZiUTlkVmlHSlNrN2hjdmpHWlBYcjJoWU1Wak9Ia0tlR0wycldUWXJUbVkyU3N6U25TRDhRemlrZ2I3V1VJYk1FSEM4MFgwb3dtU3Z0UQ?oc=5", "source_name": "Reuters", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta resumes shipping of gene therapy Elevidys to patients who can walk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWlBtTzlIWlNiY2w2TWxIYnZLelJFZ2poWnI1eXA4TUZjSnl2ZjJlWGY0VThnMVJRYUhMbGxIb1dWQmxTMEdRZjROZ2Zjc0JJM0hWaFhoUlJ4Ym9JVW5WeVBLbGdwNjJPdVZlRmF6dVpTTHNIbmgwX2FGalZLeFBkb3FGZFd6X081WFNNdTN0dFBJLUhYQjVabUVEQkZwUUxjTzktT2J5Z0gtQ2Y3QndhOUZKRS1BdVZ0allnVG9BcFc5SWdEaVFncnk0TzdZcER5TmdfVEhBZw?oc=5", "source_name": "Reuters", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta fails to win EU backing for muscle disorder gene therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYklQV2c1dTNGdFdna0RYMHNLby1yUlZrS1hfekNObWQ1NFRkbzBGMWN3bDVNdHBGOUtMYWFzN055dnUxMUd6QWhkNmJydkR2b1I2YkI4SVJIajZya2FoeFQ4bTZOcGVaNzJaWkJRRVdIcEhMNng1WnVydE45ZkpTcnJ4UG1vQkZxREdBa2VFV0dQWFpPR2VYSXdwODk5ZmUyTVYybjdjTUp1QlRZT3RpSFJYNWF2c3ZvWi12NmZlM3VLT0hBZFgxSQ?oc=5", "source_name": "Reuters", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Worth $0 Amid \u2018Unwinnable\u2019 FDA Fight, HC Wainwright Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQSU94UlV4WDJOdXlfUWpET1ZkbHVTWUhsLU1FZ0cyR1JqWkk0bkxRVEFlYkJuQWJxYkE5b2dGWFNRckxJdWpiYkVJT19wZktuWnNqUUU0V0ZZdENsSjF0c0NWNGtRZ0sxQTF4b0tuT3ZlY050czIzSGM1MXJQT0lrcVdUcGlxekRHbnFQV1lQVDNkaXN6UmZkaHdvd3VfMlhjWWUycGNob284bTg4?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These Stocks Moved the Most Today: Sarepta, Verizon, Cleveland-Cliffs, Block, Tesla, DJT, Bruker, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE44R2FHejB2RjdFWUxWUUNyQzBQenRiYWw3bUNPZ1JJaHRRRzgtTHJoV1JvZTRRME5PR3didkxrc0ZMUnFSOENYM2h5VTJDSlgtMzkxTEw3LUpvYTl3dEotSXVua24?oc=5", "source_name": "Barron's", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta share price drops again after third gene therapy death", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZmhlTGRuTDliRFRZWDFHSUlUN2NncUdpc3JYZjlBeHN0U0JSVGJ5dUM4SWE3Y2FnX0tOTHA5YTE4THhUeHA2V1NhMW5LUzlrSFR4Vmg5NkR5dkFSekpUNW1LalBVQzNNMFNWc1hSRTdBRTUzaFRScVVSQ2RwaERNY3hzYjJhZmRxZVVILTNzR2gtcHdEdExlMA?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares slump after third patient death this year", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNQ1JCTm5OcW1tQ0gweFhfa2ZnVy1xamNGV2tPSmM2bmI2QU1YYjFMeEVkU01MM0ZPd3hmT203VXp6OXBkRFlCck5YLTlnSXNxRXJjNkNlNGJqUnptS0g3R1dCTzFwRUFkczZ5TXpGbW1DcWFVTnlpVzJnekdEeGJzWDM4QnkxSEtrYmZzX2tGM2UwellaZlhPQkQ1Rzd5UUZ2WXV5S1pkcmVzQnltM0czdXl3ZHBFSWxVdzltMkVxSzM1M1JxSVkw?oc=5", "source_name": "Reuters", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Sarepta Therapeutics Stock Short Interest Rises to 32.62%", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPU3pNcWJKQ3piVXczNkJiMjZ3LUNhVVlaUmVWTzg2ZFZhclR0OHhSNXlCdzdDbktjM3ppbjZ5N2xSVlVMTUdMNGduRkJ0czh4QXNoS2ZPTi12djZwSVNCeDFUT2QxRUVCUVZqY05WcU84N2U0U3NRd0NrQmxyM0dEbWllWmtRVkxNa0xDNU15amJZdWpPVTlB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-21T13:28:00+00:00", "published_display": "21 Jul 2026 13:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T02:26:36+00:00", "published_display": "19 Jul 2026 02:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObk51bU1mR3FzU2NEWnN0YnJqQkloRVVSMDR5aHZoNlJ2UHVqNGlZdWdIQ2MxNUh0bGM5LVp5dTA3ajEzQ2ZpczFoWkE4YjM4dDhsTWVtUzk0a2xGYnZMSWh1STVDLTljQWg0Sm1mSDJoUkhvR1RCVzcxUUJKOWkwZHhfd3hVZHdhNWVMMGU5THE1TlRNeXZwVjhtRWg?oc=5", "source_name": "Market source", "published_at": "2026-07-14T00:22:00+00:00", "published_display": "14 Jul 2026 00:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9gFBVV95cUxOUG1ibFpjUk42WE1FblNsd2tPWS1qZUFFY1VhTGg3d1hGOGJfS0dVTDk1R1JkUlV3dk9QaTRmTkNDMmVpZXNhSnpSX1Q0TTNLYVgyNXd6T09kb3dfbnh2dnpORkVIdnhMNWx6NElvTTJXNFk4eFRNWGhiYlE5aXY5VzlhZU9yV3UxWFkxSzdSbmplVTRZWlJseU9jWU9uRDJva28tdzhZUzN5RDFtdG5qM2xyMXZjbmFsYXZtbW9OTUhKNkh4Z19ISFR1cXNmTFV2S0hGZHpIcmVmRUZROTNYWl9sYWxPX0J1Z0o2YWY2V0xCU2hYbFE?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:33+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQekUxZnVlZXpCSFcxOHpjU3dVTlBGOTFzakJnX1pVb3EzVDZlNm1TLW84aU1sTGpXZnNOTEVkVEFnVHlFem1ET0JsY0x1Uy15d25JV0dZLXNVQnZwaTVpeXVVTXgxU0YyQ3J1bHlyWGFhWGdhbmc2VmhwRTctanJ2WURjYVVZTFFLRmNadWJldDdsdHU2V1c0ZHlabTM0aGhkTDV3Z3hzQmhrS0VIZmxhVE5JSGlXYjhZajBpYWRuZEdnUHZwWGtCUmh2RVlUM3dRQS00?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics options trading jumps to 5,295 contracts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQOXYtV0ZEV2J3WjRUUi13anhKNUVMOGZYY1czRkV3MWQ1TXNCUFdnX0lScmlSeVdhU1lVSlEzakViZDhvaEdicXBIMXkzbGcwMTI2Z2lJTi1LalhlOHc2eFN4eXZRTkdDbXhXRUZtQktOOFYwOTZHeUdrUFZ6VWNQVDVzZjk1ZHRENUZJNmZsQ0c4bVVQT0VlWUVZTmhjbk4zR0JnZzl3V3AySG9KQ0RjNmdxU204a1pucjlheXp2MA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a Potential 43.7% Upside in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxPeGtMV3dsYmlHdnZYTnBPcUdBb0l0Q3hnZy1nNEl1UklOX3ZiMzcxd3NGOElOcF9ybEttYldnOHpCOW5qMExmc25XYkdhTU9UNlBNTExiMm5YdWJpS2o2cXpMSTNGcndtT1B3ekVwOVg4TmNtU0ViVFJHRXN1OWhVbENNZ0ZTcHJrTnFNOUdNTjlselA3Zld4TUhjQWIyUU1tYno4cFJOMFhhWWhBRS1MeGw3UDFHYV9Ea1JZZDZDcU1SYVctYlp1a3RZRVRJVVgzVWlISzNkT2hjU1duMERhU2xUREFCZw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQWTEzWXI2NXhNMFlmREM0Yzl0elQ0WWtuTG1uV0ZWUnlaMG9Feno0OVg3cGV2WXZqZ0U1NVpFWTZobGdZU01GUF8tU01fZWVLUDFRSXlxV0oxamdIbEFIbTM1cDVxNjFKQkM1RmZjMWVlVW9ITFBVYmIyOENmMG5Xd0ZnYm1DZkMxcHN0c21BaDNLTUF2b0VDenEtU05oOHk4MmVQMTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 23% Potential Upside in the Biotech Arena", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQRmZDQzFrS0t1SGk1OGx0SF8xZVhzSEIyVEtyRklrYjdrWHpXbGYzalV4UFZZbzNnWmkyaEppWl9uRDJIcUFWLWRJWkJqQ2RkeUp3cWZUYkxoU2Y2MWVqVnplakpNdXhUNXhMQmgxeTV3bjY1N3d0cUhFbGVOcEl5RVZZMV96Q3B4VVVQUVFVbzEycWNFTUEzUHhORHlZM2NIZ2pfMU5weTdsRkZJMmFlTUVwb1pSUnEycnYxWlpjMF9Pb0VndDNQMGMtemEtUjdxNzIxa1lvdi04MUVNOTlhaWdR?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQdTh2S3pWR3ZmN3YyN0twbGhqb2tROXV6REtUN21xODh4MWhNR0pEb3VKb1N6VE9UUkprN3lQb052OGl2ZE5FdUdsMEtlWkIyRE1wTm1OR1RabkZYQm10TExvTFcxMk5iaUU2WlhkaFIyekdna2pRRGpGejBHZjA2MkV3Zkc3bXpFbHR4MFpSem5tZ0dvc0liSVZ6Y2xxMU9HREtwU2Y3N0pwSTQyWFE?oc=5", "source_name": "Market source", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQZVBVbDFVMnJpUlo4NVN3SDVmQ01pMEE2NktHbVdhS0dUenotaUptTnJnOWF2dXhuUm5hdHozbHFCM1AwWG84LVA3OElZLW1SVC1JWWpMT2I3WGtESmN2WlZncUY4TlhPR1U2eDNFa1dURlVVWlBRUHVWNHl0ZzJHdDNmY2VFTU9OX2s2aFFEa1NIZDg1TFVDQ1pRQjFESWlXVnJWbGJsUjRLckRiV1Zr?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOR3hMTUpuOVg4X3dmZ056QmVEdko1SkUxbGJIcE00ZHBBNUpjN2JYSGxIOV9HT3lfLWotckZLRTVYUEdaT29fMFRZU3BtbjF3ZFY3bWY0emJYSkJHLUh6STZzV0VXSXBfMTJoSDJuVTIyMlJDdEZpQmZmdGdfUXlqM1NyWlhuMFY5Xzk5YUR6eXFzRF9KU0ZoeWNMMjRQZmR5NFhpZTNtMTVma21WbWpF?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics shares drop 10% on lower Elevidys revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcmZlM2VlUi1oOHU0MTNXdmhLREVqUmZ3d3dPV05BelIzMFVnbHExWEVLUFhad2pEUUtDbHlPamNMTGprSTItbk12UzN5QjZUbUM2VjVqWjM0TU9RVUhVZGN5ZS1DcHIzQV84dFBmdTNUVzRSQVZDWEhkS3ZZd1N5TDY1b3ZtbDkyaXpndUtvUDBPb0V1TmIxNjdlU2xCVHdHdG80VzFiSm5FMUJZdnpRM2VyaXFpUkZWaUZLTkhwSjQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Stock Falls as Investors Eye RNA Drugs, Despite Elevidys Gene Therapy Sales Outperforming Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxORFJfMXlKbjBCX2Y3MkxmajlwbzUtdGoxb29sdlJOWC1ZY3pBYnZXRzJwcmJSM29DUXVuVVBUaC1RLWFpczc5dDlTZ2JIa2dkX1lOcW82UnFjZF9ndkRRdmFPVkJpaTNoVXBmVjNOQ3M3Um95S2Q0R2NxRlNZWkh2X2Uzc1lyd0xpZjhFUjBKbDE0dzlpNzg4TGVCS0VmaEZmZVBRZVd1SnNQVXdjSm4wTmZkbVNiUVpiTkd4aWxNb2hfN3dmLVpqeE1tSXdOUWM?oc=5", "source_name": "geneonline.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNaS1Rb0lPUi1jNlpkSGpWd1g1V3FYN05mclpZamY3RDFNTGxKZG5wTVdQdl9TaGI0aXBQVVEzY05MLVRYSmk0ZDAwaGx5YmpaMmNPY0xQNHBoSTNzdjJwTXRxeXZEMkp6MHhvLTFyS3pvWDdFRHIzWmRnME9UX3hGLXBSUC1QaEpvUFRmNXhxY01IeEE3Wm1GZ1NKekw2STVQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOamcwUjJmNDlTSWhXb2wyeEpGNmlEWWI3Z3RLSGpYdU5ROXBHTlJ1LUp1aU45d3JYUmt5ZnVjQnhqSnV1a0hQSWtPLUFyaTZTa1UxTG1GUmZlRXBaSXUxdUM5ZUlfWExES1ljUktSY3ZlbVhjZmRKcU9OOG9UcXRuVnpRdkgwUndPeV9zN1FpdTdHdzN5S3JVMkFKNEduazZNR19jOXROckFBaXAtNlVF?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta stock surges 14% on early siRNA trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPUzVGZk9jOFNrME80WjlLMDlOMmhDeU9nNlp1ZllBMklSWHlVekNDYUlDY2pBVmxfVnhPcV9pdEE2XzhBSE5Wa2NXYkxxaGFGT0VqTkhpLTJ0Zm9iNXk5QTFhYUJCOGp4STdGRnA0aVFaVXZtZS0tUGMyblc1dERpLUkxM095SkpESlE5TzZNUnJXeTExU0lvOWxmUXNCVWFhR2lDR1VTUWpuTkFJcFNDRQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho reiterates Sarepta stock rating on positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZHNiNkJBblc1cV9CWmdFSVRBTmhDeHV4cHhQMl9UTFpoUzQxVGVQbksxVnkwem1xZDREYko0MlhrMWVWMTlMc2FSVkpXWGNTUGJDNWY1bE5WM1B1aldsOURkRnc0WC1hdlFpaXFicnVsak1CdWVwWXptZklKLU96LUFnTDVQSWZXYnVudXJvX3lSR1pYM3dSRmVKN1NCWW42VjVvQlN4MHF2U01CUmlsQVNvcFp0a3ppNE83S3V3?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink reiterates Market Perform on Sarepta stock after siRNA data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcHFkUFFiNnVXQzFKaWx4c1FwVWtfN2hNZ2F0andXM1hsMzB2S0VBanUta3dYcnNMS1l3X3pEdWd0SlFBd2tOdE8yVkhLazFlejFIbnF6SmR4SE1mSFMyWkl5eHhPV0RObDlXSWNfZlZCMUtwX3htUUdTaG5sbXdwd2JwVzBFaTNTcFY1UXhBUFZYMzJablJUeGRyd0Y5MFo1UHZoQVhiTUI4djBEZHAxeTU3dUE0WXRySFZxOVVjS3RjTk1la2c?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOZDVxTV9xbXFhLVk3emNJVklnQ0NGT1pKUzFPQU0xVEdjblRhbGtTTDBVQlhnczV6MjlMMHl5blhqaHZnZUNjZHE5MjdES3g5TE1fQllhSWtXVU03ejlDX1RhWFRGYXlXTDVwY0dINUZ0T1lURVZscm01VVE0b1MyUTc3YWR2QkxtNlk0RXFtalpqcms2WDN2TDBOZHJ4djg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan maintains Neutral rating on Sarepta stock after positive 3-year data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOQjVvS1dRcXZpU1hTVWhGT0o4djBfUG1UczZKam5uUmVVNmIyVU9WbEdsQlBJVXFBZjdFTWxDcjZtZWx1aTdBWUUwd2tvOWN5NGp3VVVuWVVSdDlUYllJRlJta3FyR254bUtfRDFuczJCRlA5UEFZcHJCVnZoTGo0QjJjamc4MEhDYnVJOExqYm5vaXFrZU1Wc2RPTk5lM2N3TjQ0YldaMDRCRERtRU5yekZPYllpWjV5M2stdTFnMXVLZXFSc1hyUDBpWUIzUDRrM2c?oc=5", "source_name": "Investing.com", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQZVFia2lQSldTSVNtT1JvNEd1aU5PYnF3dTR6QmRsUjZvaFhJV2hjSUpwSEdJYi1YYm00RHM4ZDdyamQ0ZDJmTFEyV0dIaFJqSTQtUmZoUldPN3JIQXk1YzkzM1lNa0w3OTVWNVZrSTdPNVNnMllFLUtSa1pfQXhiTnZUTVotYUhNMTYtQ1ZWNW5HdkJGZ1JaWV9TV2Iwa1V5bnF4LVRUYk5ELWR5eWxNbHgwaXBmaVhjQnpTNzJUX0RuR1VY?oc=5", "source_name": "Investing.com", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Falls After Gene Therapy Elevidys Misses Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNUlFEQ3IxaUFwT2pzaDUxVzQ4ZWR1c0N1Ykh1SThzODhYbVJxeUtXOEZMSnNlOWdOcC1TanlKTGo4bGlORG9PeWpCN2FWd2M4LVVpUW43S090YUhCeE9meTVZSXBGa2RuTU5WU1FIMVRXVXJCYlI4Rlp2ajU4ekNad1hSbnBDU3JXdEdUQlZxWU1leHhWN25VNklQU09GcVdnZGQzRmZmTFMzVmsyWnc?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares tumble on trial failure, weak Elevidys outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNNUM0N2d4V0VQU3BreE5TVmdBTWtsWkVhSEFqZ3FiY0RGNnd5Z2VwLUdlRjd2aHo0Q1FybnBuU3RmNlF3RW5VUmNzNE1BamhZRWY3aGtjaTQwSlZNcTB1NWF5QnVLQ2VsTm5fcDNqYUVWNkNuNUdtQVg1cm94Y0JZRl9DR3N2WDU4QVJFMG80YTczaXd2YmlPN3dsdzJ6OE1ERTRMczc2NlBWdXBsdExaLVB3OHRQTDA0eE1OdUl5dU1lQTYxU0pqQ3FXSQ?oc=5", "source_name": "Reuters", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Sarepta Stock Jump 20% On Tuesday? Here\u2019s What JPMorgan, Bernstein, Barclays Said About Elevidys", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOTmJLdXRqQ3JuejRqZTNobEs4MWtPN2lidlJZa3B1dUh0dzI2ZHJTY29nanBlbXdZeUtMZFp4aU4wV255ZnczQVltUEF5R1Z6Y2ZHckpqX1E2S2E1UGhxZ3I3Y05IaV9SWjBYWG9yWWF2M3NhQlA3S2JYcHM2Z3d0bVZ6amMzUDgzcXRFMHNnMHFwWU9QRk81WFF1ZDRNU05VUG9WUW01QzNQWHRKS1lqUzI5dk8?oc=5", "source_name": "Stocktwits", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares rebound after shipments of gene therapy Elevidys resume in US", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQT2ExUVAyeDBlSWc3cUUzS2tjVnZvVFFLY2g1ZU9iVk9kX3JpMjFDRnFHSHExUjNYVGlUWExzZnZhcndBYmVPN3hZZnVMb0ZZREdMSlFrRzdKRXVLb09scS1HcFBETTJDaDdoZ0tITDl6cF9CYTM4OTVFeldUeGMxMkdTSGtFX0U3bkFsMmZiUTlkVmlHSlNrN2hjdmpHWlBYcjJoWU1Wak9Ia0tlR0wycldUWXJUbVkyU3N6U25TRDhRemlrZ2I3V1VJYk1FSEM4MFgwb3dtU3Z0UQ?oc=5", "source_name": "Reuters", "published_at": "2025-07-29T07:00:00+00:00", "published_display": "29 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta resumes shipping of gene therapy Elevidys to patients who can walk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPWlBtTzlIWlNiY2w2TWxIYnZLelJFZ2poWnI1eXA4TUZjSnl2ZjJlWGY0VThnMVJRYUhMbGxIb1dWQmxTMEdRZjROZ2Zjc0JJM0hWaFhoUlJ4Ym9JVW5WeVBLbGdwNjJPdVZlRmF6dVpTTHNIbmgwX2FGalZLeFBkb3FGZFd6X081WFNNdTN0dFBJLUhYQjVabUVEQkZwUUxjTzktT2J5Z0gtQ2Y3QndhOUZKRS1BdVZ0allnVG9BcFc5SWdEaVFncnk0TzdZcER5TmdfVEhBZw?oc=5", "source_name": "Reuters", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta fails to win EU backing for muscle disorder gene therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYklQV2c1dTNGdFdna0RYMHNLby1yUlZrS1hfekNObWQ1NFRkbzBGMWN3bDVNdHBGOUtMYWFzN055dnUxMUd6QWhkNmJydkR2b1I2YkI4SVJIajZya2FoeFQ4bTZOcGVaNzJaWkJRRVdIcEhMNng1WnVydE45ZkpTcnJ4UG1vQkZxREdBa2VFV0dQWFpPR2VYSXdwODk5ZmUyTVYybjdjTUp1QlRZT3RpSFJYNWF2c3ZvWi12NmZlM3VLT0hBZFgxSQ?oc=5", "source_name": "Reuters", "published_at": "2025-07-25T07:00:00+00:00", "published_display": "25 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta Worth $0 Amid \u2018Unwinnable\u2019 FDA Fight, HC Wainwright Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQSU94UlV4WDJOdXlfUWpET1ZkbHVTWUhsLU1FZ0cyR1JqWkk0bkxRVEFlYkJuQWJxYkE5b2dGWFNRckxJdWpiYkVJT19wZktuWnNqUUU0V0ZZdENsSjF0c0NWNGtRZ0sxQTF4b0tuT3ZlY050czIzSGM1MXJQT0lrcVdUcGlxekRHbnFQV1lQVDNkaXN6UmZkaHdvd3VfMlhjWWUycGNob284bTg4?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These Stocks Moved the Most Today: Sarepta, Verizon, Cleveland-Cliffs, Block, Tesla, DJT, Bruker, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE44R2FHejB2RjdFWUxWUUNyQzBQenRiYWw3bUNPZ1JJaHRRRzgtTHJoV1JvZTRRME5PR3didkxrc0ZMUnFSOENYM2h5VTJDSlgtMzkxTEw3LUpvYTl3dEotSXVua24?oc=5", "source_name": "Barron's", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta share price drops again after third gene therapy death", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQZmhlTGRuTDliRFRZWDFHSUlUN2NncUdpc3JYZjlBeHN0U0JSVGJ5dUM4SWE3Y2FnX0tOTHA5YTE4THhUeHA2V1NhMW5LUzlrSFR4Vmg5NkR5dkFSekpUNW1LalBVQzNNMFNWc1hSRTdBRTUzaFRScVVSQ2RwaERNY3hzYjJhZmRxZVVILTNzR2gtcHdEdExlMA?oc=5", "source_name": "Clinical Trials Arena", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sarepta shares slump after third patient death this year", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNQ1JCTm5OcW1tQ0gweFhfa2ZnVy1xamNGV2tPSmM2bmI2QU1YYjFMeEVkU01MM0ZPd3hmT203VXp6OXBkRFlCck5YLTlnSXNxRXJjNkNlNGJqUnptS0g3R1dCTzFwRUFkczZ5TXpGbW1DcWFVTnlpVzJnekdEeGJzWDM4QnkxSEtrYmZzX2tGM2UwellaZlhPQkQ1Rzd5UUZ2WXV5S1pkcmVzQnltM0czdXl3ZHBFSWxVdzltMkVxSzM1M1JxSVkw?oc=5", "source_name": "Reuters", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 32, "sentiment_summary": {"positive": 7, "negative": 6, "neutral": 19, "score": 48, "total": 32, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 13.65, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 3.1, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 294.0, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": 4.6, "twelve_week_move": -19.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.441754, "market_dynamics_buy_signal": false, "relative_strength": -19.271719, "fair_value_gap": -59.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 28.2342, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +4.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Investing.com", "count": 8}, {"label": "Reuters", "count": 5}, {"label": "DirectorsTalk Interviews", "count": 3}, {"label": "Bloomberg.com", "count": 2}, {"label": "Quiver Quantitative", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "geneonline.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, +4.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Sarepta Therapeutics Stock Short Interest Rises to 32.62%"}], "updated_at": "2026-07-21T19:35:31.399415+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}